Q32 is honored to be a part of BioSpace, Inc.'s NextGen Bio Class of 2021! A huge congratulations to our colleagues who were also recognized. http://bit.ly/2L4b9Sa
Q32 Bio Inc.
Biotechnology Research
Waltham, Massachusetts 4,025 followers
Revolutionizing the future of targeted immune therapeutics
About us
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
- Website
-
https://www.q32bio.com/
External link for Q32 Bio Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Inflammatory, Autoimmunity, Research, and Clinical Development
Locations
-
Primary
Get directions
830 Winter St
2nd Floor
Waltham, Massachusetts 02451, US
Employees at Q32 Bio Inc.
-
Kelly LeBoeuf Fahnoe
Director, Protein Science at Q32 Bio Inc.
-
Simon Read
Founder and CEO Mariana Oncology, Advisor Atlas Ventures, Co-founder Triana Biomedicines
-
JoAnn Gifford
Senior Accountant
-
Hong Wu, MD, PhD, DABT
Vice President, Head of Clin Pharm & Nonclinical Dev at Q32 Bio Inc.
Updates
-
Q32 Bio Inc. warmly welcomes Victoria Russell, our new Clinical Trial Manager, to our growing clinical team!
-
-
Q32 Bio Inc. extends a warm welcome to Lee Kalowski, our new President & Chief Financial Officer! Read more about Lee and Q32 Bio here: https://lnkd.in/eHZETCFM https://lnkd.in/dBbVNJ6
-